Northern RNA Inc. Signs Memorandum of Understanding with Alexander Chemical L.P.
Posted on February 03, 2025 by Northern RNA
CALGARY, Alberta February 3, 2025 – Northern RNA Inc. is excited to announce that we have signed a Memorandum of Understanding (MOU) with Alexander Chemical L.P. (ACLP), a majority First Nations owned and Canadian owned company.
Through this MOU, NRNA and ACLP will explore new opportunities for mutual benefit, aiming to strengthen Canada’s life sciences and pharmaceuticals sectors.
This marks an exciting milestone for Northern RNA as we seek to strengthen our presence in the growing life sciences sector in Canada and internationally.
Through this agreement, NRNA and ACLP will work together to drive meaningful impact by committing to joint activities that foster sector development and innovation. We will be actively sharing knowledge, expertise, and resources, all with the aim of enhancing research and development capabilities, expanding commercial opportunities, and driving diversification within the industry.
Northern RNA is a leading CDMO with a focus on RNA-based personalized and precision medicines, and vaccines (including H5Nx, which represents an emerging and growing international health risk). Our role in vaccine support is critical to ensuring preparedness and a safe, domestic supply of vaccines and vaccine raw materials is available for all Canadians.
Our partnership with Alexander Chemical L.P. reflects our dedication to building relationships that create mutual value while contributing to the broader development of Canada’s life sciences ecosystem. We believe that this collaboration will open new avenues for innovation and growth, with a focus on enhancing the biomanufacturing landscape and supporting the development of new and exciting technologies.
As we embark on this journey, Northern RNA is proud to stand alongside Alexander Chemical L.P. in promoting an inclusion-first strategy for Canadian-owned businesses and advancing Canada’s position as a global leader in biomanufacturing and life sciences. We are eager to explore the opportunities this partnership will unlock, and we remain committed to fostering sustainable growth in our industry for the benefit of all stakeholders.
About Northern RNA Inc.
Founded in 2020 to address unmet global demand for the manufacturing of vaccines and vaccine components, Northern RNA (https://northernrna.com/) is a leading Contract Development and Manufacturing Organization (CDMO) specializing in the manufacturing and production of Nucleic Acid products used in applications including mRNA vaccines, DNA vaccines, mRNA therapies, Gene Editing and Gene therapies. Our goal is to provide secure, clinical to commercial scale, GMP-grade manufacturing for our customers across the globe.
Northern RNA Business Contact
Thomas Hansen
Vice President, Corporate Affairs
thansen@northernrna.com
#CDMO #RNA #mRNA #LNP #Lipids #oligo #Biomanufacturing #Drugdevelopment #ManufacturingaBetterFuture